旨在评估全球宫颈癌筛查计划中筛查结果呈阳性后对分诊测试的依从性以及转诊癌前病变治疗的比率。我们检索了三个电子数据库（Medline、EMBASE 和 Web of Science），查找以英语发表的文章2018年1月1日至2023年12月31日。我们纳入了报告宫颈癌筛查项目中分诊检测和癌前治疗合规率的研究。对 ClinicalTrials.gov 进行了审查，没有发现更多研究。综合检索策略确定了 1,673 个标题，其中筛选了 858 个标题和摘要，并评估了 113 篇全文文章的资格。共有33项研究符合纳入标准并纳入荟萃分析。其中33项研究纳入系统评价和荟萃分析。筛查呈阳性的女性对分诊测试的平均依从率为 77.1%，对转诊治疗的平均依从率为 69.4%。依从性因国家收入水平、筛查指南方法和目标人群而异。目前的依从率低于世界卫生组织消除宫颈癌全球战略设定的90%目标。对筛查呈阳性的参与者随访不充分，揭示了筛查计划与临床护理之间的差距。版权所有 © 2024，美国妇产科医师学会。由 Wolters Kluwer Health, Inc. 出版。保留所有权利。

To assess the rates of adherence to triage testing after positive screening results and referral to treatment for precancerous lesions in global cervical cancer screening programs.We searched three electronic databases (Medline, EMBASE, and Web of Science) for articles published in the English language from January 1, 2018, to December 31, 2023. We included studies reporting the compliance rate of triage testing and precancer treatment in cervical cancer screening programs. ClinicalTrials.gov was reviewed, and no more studies were identified.The combined search strategies identified 1,673 titles, of which 858 titles and abstracts were screened and 113 full-text articles were assessed for eligibility. A total of 33 studies met the inclusion criteria and were included in the meta-analysis.Thirty-three studies were included in the systematic review and meta-analysis. The average compliance rate for women screening positive was 77.1% for triage testing and 69.4% for referral to treatment. Compliance varied by country income level, screening guideline approach, and target population.The current compliance rate was lower than the 90% target set by the World Health Organization's global strategy to eliminate cervical cancer. Inadequate follow-up of participants screening positive revealed a gap between the screening program and clinical care.Copyright © 2024 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.